Mineralys Therapeutics Inc’s recent filing unveils that its Chief Medical Officer Rodman David Malcom unloaded Company’s shares for reported $0.17 million on May 14 ’25. In the deal valued at $15.29 per share,11,366 shares were sold. As a result of this transaction, Rodman David Malcom now holds 106,669 shares worth roughly $1.71 million.
Then, Rodman David Malcom bought 11,366 shares, generating $173,774 in total proceeds.
Before that, Slingsby Brian Taylor bought 259,259 shares. Mineralys Therapeutics Inc shares valued at $3,499,996 were divested by the Director at a price of $13.50 per share. As a result of the transaction, Slingsby Brian Taylor now holds 8,903,838 shares, worth roughly $142.73 million.
H.C. Wainwright initiated its Mineralys Therapeutics Inc [MLYS] rating to a Buy in a research note published on July 10, 2024; the price target was $30. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Wells Fargo began covering MLYS with “an Overweight” recommendation on March 07, 2023. Stifel started covering the stock on March 07, 2023. It rated MLYS as “a Buy”.
Price Performance Review of MLYS
On Tuesday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock fall -0.99% to $16.03. Over the last five days, the stock has lost -0.93%. Mineralys Therapeutics Inc shares have risen nearly 30.22% since the year began. Nevertheless, the stocks have risen 19.18% over the past one year.
How much short interest is there in Mineralys Therapeutics Inc?
A steep rise in short interest was recorded in Mineralys Therapeutics Inc stocks on 2025-05-15, growing by 1.11 million shares to a total of 7.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 6.09 million shares. There was a rise of 15.47%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 07, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
